Payment overview · 2025
General Payments
$14,265.50
152 reported records · 16 companies
Healthcare provider profile · identity verified
Pendleton Brewster Wickersham, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology · SAN ANTONIO, TX · NPI 1053380048
Verified facts
What the public records show
CMS Open Payments records show Pendleton Brewster Wickersham, M.D. received $14,265.50 in general payments during 2025 across 152 reported records.
E.R. Squibb & Sons, L.L.C. accounted for 52.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Benlysta, Enbrel, Orencia, Otezla, Rinvoq, Saphnelo.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Rinvoq by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENBREL as an associated drug or biological on 9330 records involving 2094 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Enbrel by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Otezla by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SAPHNELO as an associated drug or biological on 16430 records involving 3390 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Saphnelo by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ORENCIA as an associated drug or biological on 10404 records involving 2463 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Orencia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BENLYSTA as an associated drug or biological on 19884 records involving 5034 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Benlysta by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SIMPONI as an associated drug or biological on 23185 records involving 7011 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Simponi by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $7,510.98 | 52.6% | 14 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $5,060.39 | 35.5% | 14 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $342.04 | 2.4% | 33 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $328.34 | 2.3% | 14 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $315.38 | 2.2% | 28 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $248.30 | 1.7% | 16 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $230.56 | 1.6% | 20 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $57.98 | 0.4% | 4 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $39.03 | 0.3% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$37.41 | 0.3% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $22.99 | 0.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.38 | 0.1% | 1 | 2025 |
| Aurinia Pharma U.S., Inc. | Unresolved — no canonical attribution shown | $14.86 | 0.1% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $14.17 | 0.1% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $14.04 | 0.1% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $13.65 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $9,667.50 | 3 |
| Food and Beverage | $2,302.22 | 144 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,400.00 | 1 |
| Travel and Lodging | $795.79 | 3 |
| Education | $99.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SAPHNELO Normalized: saphnelo |
Biological | AstraZeneca Pharmaceuticals LP | $1,788.90 | 11 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $342.04 | 33 | 2025 |
Source payment records
|
|||||
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $312.15 | 13 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $248.30 | 16 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $159.14 | 14 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $143.21 | 11 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $66.64 | 7 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $57.98 | 4 | 2025 |
Source payment records
|
|||||
| ENBREL Normalized: enbrel |
Biological | Amgen Inc. | $55.85 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $55.85 | 4 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $39.03 | 2 | 2025 |
Source payment records
|
|||||
| STEALTHSTATION S8 PLATFORM Normalized: stealthstation s8 platform |
Device | Medtronic, Inc. | $37.41 | 1 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $36.42 | 5 | 2025 |
Source payment records
|
|||||
| ORENCIA Normalized: orencia |
Biological | E.R. Squibb & Sons, L.L.C. | $35.61 | 5 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $25.10 | 3 | 2025 |
Source payment records
|
|||||
| TERIPARATIDE Normalized: teriparatide |
Drug | Almatica Pharma LLC | $22.99 | 1 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $19.68 | 2 | 2025 |
Source payment records
|
|||||
| LUPKYNIS Normalized: lupkynis |
Drug | Aurinia Pharma U.S., Inc. | $14.86 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $14.17 | 1 | 2025 |
Source payment records
|
|||||
| HADLIMA Normalized: hadlima |
Drug | Organon LLC | $14.04 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $13.65 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $9.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BENLYSTA benlysta |
2025 | Benlysta | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ENBREL enbrel |
2025 | Enbrel | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ORENCIA orencia |
2025 | Orencia | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| RINVOQ rinvoq |
2025 | Rinvoq | 2024 | 95 | exact normalized | Medicare Part D |
| SAPHNELO saphnelo |
2025 | Saphnelo | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | RINVOQ open payments reported associated product |
CMS Open Payments — General Payments 279238 supporting records · 34343 recipient NPIs · example record 1201352600 |
Rinvoq · 2024 Exact normalized brand match · 1 Part D row |
95 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | ENBREL open payments reported associated product |
CMS Open Payments — General Payments 9330 supporting records · 2094 recipient NPIs · example record 1226877474 |
Enbrel · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SAPHNELO open payments reported associated product |
CMS Open Payments — General Payments 16430 supporting records · 3390 recipient NPIs · example record 1206131348 |
Saphnelo · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ORENCIA open payments reported associated product |
CMS Open Payments — General Payments 10404 supporting records · 2463 recipient NPIs · example record 1184378623 |
Orencia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | BENLYSTA open payments reported associated product |
CMS Open Payments — General Payments 19884 supporting records · 5034 recipient NPIs · example record 1190332353 |
Benlysta · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | SIMPONI open payments reported associated product |
CMS Open Payments — General Payments 23185 supporting records · 7011 recipient NPIs · example record 1174257377 |
Simponi · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 685 | 121 |
| Prednisone | Prednisone | 467 | 128 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 464 | 134 |
| Methotrexate | Methotrexate Sodium | 305 | 90 |
| Gabapentin | Gabapentin | 225 | 64 |
| Duloxetine Hcl | Duloxetine Hcl | 195 | 59 |
| Levothyroxine Sodium | Levothyroxine Sodium | 149 | 40 |
| Celecoxib | Celecoxib | 105 | 39 |
| Tramadol Hcl | Tramadol Hcl | 104 | 40 |
| Tizanidine Hcl | Tizanidine Hcl | 97 | 25 |
| Rinvoq | Upadacitinib | 95 | 15 |
| Methylprednisolone | Methylprednisolone | 89 | 62 |
| Trazodone Hcl | Trazodone Hcl | 86 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 76 | 18 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 73 | 21 |
| Omeprazole | Omeprazole | 68 | 17 |
| Meloxicam | Meloxicam | 66 | 25 |
| Cephalexin | Cephalexin | 61 | 45 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 59 | 21 |
| Leflunomide | Leflunomide | 57 | 21 |
| Humira(Cf) Pen | Adalimumab | 54 | 12 |
| Allopurinol | Allopurinol | 48 | 14 |
| Potassium Chloride | Potassium Chloride | 47 | 13 |
| Azathioprine | Azathioprine | 44 | 16 |
| Benlysta | Belimumab | 43 | suppressed |
| Colchicine | Colchicine | 42 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 39 | 26 |
| Baclofen | Baclofen | 38 | suppressed |
| Folic Acid | Folic Acid | 37 | 12 |
| Alprazolam | Alprazolam | 36 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 36 | 12 |
| Sertraline Hcl | Sertraline Hcl | 33 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Otezla | Apremilast | 32 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 31 | 13 |
| Pregabalin | Pregabalin | 29 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Sulfasalazine | Sulfasalazine | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Metaxalone | Metaxalone | 24 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 23 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 22 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 22 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 22 | suppressed |
| Azithromycin | Azithromycin | 21 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Lisinopril | Lisinopril | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Enbrel | Etanercept | 19 | suppressed |
| Sulfasalazine Dr | Sulfasalazine | 19 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 16 |
| Orencia Clickject | Abatacept | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 17 | suppressed |
| Enbrel Sureclick | Etanercept | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 16 |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Kevzara | Sarilumab | 16 | suppressed |
| Savella | Milnacipran Hcl | 16 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Taltz Autoinjector | Ixekizumab | 15 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Saphnelo | Anifrolumab-Fnia | 14 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 14 | suppressed |
| Dapsone | Dapsone | 13 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 13 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 13 | suppressed |
| Bimzelx Autoinjector | Bimekizumab-Bkzx | 12 | suppressed |
| Gammaplex | Immun Glob G(Igg)/Gly/Iga 0-50 | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Gammaked | Immune Globul G/Gly/Iga Avg 46 | 11 | suppressed |
| Leucovorin Calcium | Leucovorin Calcium | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Orencia | Abatacept/Maltose | 11 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Simponi | Golimumab | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $14,265.50 · 152 records | E.R. Squibb & Sons, L.L.C. | BENLYSTA, Bimzelx, COSENTYX, ENBREL, EVENITY, Gamunex-C, HADLIMA, KRYSTEXXA, LUPKYNIS, ORENCIA, OTEZLA, PROLIA, RINVOQ, SAPHNELO, SKYRIZI, STEALTHSTATION S8 PLATFORM, Senza, TAVNEOS, TERIPARATIDE, TREMFYA, Tymlos, UPLIZNA | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Benlysta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error